drugset / Trial / NCT02273219
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Non-randomizedSequentialOpen-labelTreatment
Summary
Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and BYL719.
Timeline
- Start
- 2014-11-19
- Primary completion
- 2017-10-18
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 200 mg | Oral |
| Subject | Alpelisib | Small molecule | 250 mg | Oral |
| Subject | Alpelisib | Small molecule | 300 mg | Oral |
| Subject | Alpelisib | Small molecule | 350 mg | Oral |
| Subject | sotrastaurin | Small molecule | 100 mg | Oral |
| Subject | sotrastaurin | Small molecule | 200 mg | Oral |
| Subject | sotrastaurin | Small molecule | 300 mg | Oral |